Phage therapy targeting Escherichia coli - a story with no end?

Show simple item record

dc.contributor.author Bolocan, Andrei Sorin
dc.contributor.author Callanan, Julie
dc.contributor.author Forde, Amanda
dc.contributor.author Ross, R. Paul
dc.contributor.author Hill, Colin
dc.date.accessioned 2017-08-01T11:29:26Z
dc.date.available 2017-08-01T11:29:26Z
dc.date.issued 2016-11-09
dc.identifier.citation Bolocan, A. S., Callanan, J., Forde, A., Ross, R. P. and Hill, C. (2016) 'Phage therapy targeting Escherichia coli - a story with no end?', Fems Microbiology Letters, 363(22), fnw256 (5pp). doi:10.1093/femsle/fnw256 en
dc.identifier.volume 363 en
dc.identifier.issued 22 en
dc.identifier.startpage 1 en
dc.identifier.endpage 5 en
dc.identifier.issn 0378-1097
dc.identifier.uri http://hdl.handle.net/10468/4414
dc.identifier.doi 10.1093/femsle/fnw256
dc.description.abstract Bacteriophages (phages) or bacterial viruses have long been proposed as an alternative therapy against antibiotic-resistant bacteria such as Escherichia coli. Even though poorly documented in the scientific literature, a long clinical history of phage therapy in countries such as Russia and Georgia suggests potential value in the use of phages as antibacterial agents. Escherichia coli is responsible for a wide range of diseases, intestinal (diarrhoea) and extraintestinal (UTI, septicaemia, pneumoniae, meningitis), making it an ideal target for phage therapy. This review discusses the latest research focusing on the potential of phage therapy to tackle E. coli-related illnesses. No intact phages are approved in EU or USA for human therapeutic use, but many successful in vitro and in vivo studies have been reported. However, additional research focused on in vivo multispecies models and human trials are required if phage therapy targeting E. coli pathotypes can be a story with happy end. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Oxford University Press en
dc.rights © 2016, FEMS. All rights reserved. This is a pre-copyedited, author-produced version of an article accepted for publication in FEMS Microbiology Letters following peer review. The version of record: Bolocan, A. S., Callanan, J., Forde, A., Ross, P. and Hill, C. (2016) 'Phage therapy targeting Escherichia coli - a story with no end?', Fems Microbiology Letters, 363(22), fnw256 (5pp) is available online at http://dx.doi.org/10.1093/femsle/fnw256 en
dc.subject Phage therapy en
dc.subject AIEC en
dc.subject UTI en
dc.subject STEAEC en
dc.title Phage therapy targeting Escherichia coli - a story with no end? en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Colin Hill, Microbiology, University College Cork, Cork, Ireland. +353-21-490-3000 Email: c.hill@ucc.ie en
dc.internal.availability Full text available en
dc.check.info Access to this article is restricted until 12 months after publication by request of the publisher. en
dc.check.date 2017-11-09
dc.date.updated 2017-08-01T09:20:55Z
dc.description.version Accepted Version en
dc.internal.rssid 405304100
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Janssen Biotech en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Fems Microbiology Letters en
dc.internal.copyrightchecked Yes en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress c.hill@ucc.ie en
dc.relation.project Science Foundation Ireland (SFI/12/RC/2273; SFI/14/SP); Janssen Biotech (Research Grant) en


Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement